![Desmopressin in Bleeding Disorders [electronic resource] /](/search/themes/bootstrap3/images/libros.png)
Desmopressin in Bleeding Disorders [electronic resource] /
I. Hemostasis and Desmopressin -- Regulation of Haemostasis: The Role of Arginine Vasopressin -- Von Willebrand Factor and P-Selectin Targeting to and Release from Endothelial Cell-Specific Storage Granules -- Factor VIII in Monkeys, Effect of DDAVP Analogues -- Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia -- Molecular Mechanisms of Cellular Responses to DDAVP -- II. Phemacology and Pharmacodynamics of Desmopressin -- Some Pharmacological Properties of Desmopressin -- Pharmacokinetics of Desmopressin -- Fall-Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients -- Toxicity of Desmopressin and Related Peptides -- The Hemodynamic and Coagulant Effects of dDAVP are Specific Extrarenal V2-Receptor Responses -- The Vasopressin Antagonist SK&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in vivo -- Non-Responsivess of t-PA, u-PA, and vWF to DDAVP -- III. Desmopressin in Renal Disease -- Control of Bleeding in Uremic Patients -- Hemostatic Effectiveness of Desmopressin in the Bleeding Disorders of Uremia -- Renal Function and Thromboembolism in High Dose Desmopressin Treatment -- IV. Desmopressin and Platelets -- DDAVP Corrects the Platelet Dysfunction Produced by Cardiopulmonary By-Pass, Hemodialysis and Prolonged Storage: Re-Expresion of Glycoprotein Ib on the Platelet Membrane -- Desmopressin in the Treatment of Congenital and Acquired Defects of Platelet Functions -- The Effectiveness of Desmopressin in Patients with Disorders of Primary Haemostasis -- Clinical Efficacy of Desmopressin and Consistency of Responses to Separate Infusion in Patients with Prolonged Bleeding Time Due to Congenital Platelet Defect -- V. Desmopressin and Surgery -- Desmopressin, von Willebrand Factor and Surgery -- Desmopressin in Cardiac Surgery with Extra-Corporeal Circulation -- Desmopressin Corrects the Hemostatic Disorder Induced by Dextran and Regional Anesthesia in Total Hip Replacement -- VI. Desmopressin and Blood Donation -- Effects of Desmopressin on Normal Donors in Plasma Exchange Donations -- The Use of DDAVP in Blood Donors to Increase the Yield of Factor VIII in the Preparation of Factor VIII Concentrates -- VII Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease -- Epidemiology of Mild and Moderate Hemophilia A and von Willebrand’s Disease -- An Overview of Gene Alterations in Mild Hemophilia and von Willebrand Disease -- DDAVP — Clinical Use and Therapeutic Limitations in Patients with Congential Bleeding Disorders: The Auckland Experience -- Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia A and von Willebrand’s Disease -- Management of Spontaneous Bleeding and Prevention of Bleeding after Dental Extractions and Other Surgical Procedures in Mild Hemophilia A and von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center -- Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the In-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project -- Desmopressin: An Overview of Present and Future Indications with a Review of Investigations Performed at the University of Manitoba, 1981–1989 -- VIII. Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease (Second Part) -- Desmopressin in Acquired Hemophilia -- Intravenous and Subcutaneous Desmopressin: Clinical Results -- Intranasal Application of DDAVP: Biological Function, Pharmacokinetics and Reproducibility -- Use of Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders -- Nasal Spray Desmopressin: Laboratory and Clinical Implications -- IX. Side-Effects and Adverse Reactions of Desmopressin -- DDAVP and Tachyphylaxis in Healthy Subjects -- Biological Responses to Repeated Doses of Desmopressin (DDAVP) in Patients with Hemophilia and von Willebrand’s Disease -- Myocardial Infarction and Stroke: Is the Risk Increased by Desmopressin? -- X. Recapitulation -- DDAVP in the Management of Congential and Acquired Bleeding Disorders: Solved and Unsolved Issues.
| Main Authors: | , , , |
|---|---|
| Format: | Texto biblioteca |
| Language: | eng |
| Published: |
Boston, MA : Springer US : Imprint: Springer,
1993
|
| Subjects: | Medicine., Pharmacology., Hematology., Biochemistry., Medicine & Public Health., Pharmacology/Toxicology., Biochemistry, general., |
| Online Access: | http://dx.doi.org/10.1007/978-1-4615-2922-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | I. Hemostasis and Desmopressin -- Regulation of Haemostasis: The Role of Arginine Vasopressin -- Von Willebrand Factor and P-Selectin Targeting to and Release from Endothelial Cell-Specific Storage Granules -- Factor VIII in Monkeys, Effect of DDAVP Analogues -- Possible Involvement of Serotonin in the Haemostatic Action of DDAVP in Patients with Uraemia -- Molecular Mechanisms of Cellular Responses to DDAVP -- II. Phemacology and Pharmacodynamics of Desmopressin -- Some Pharmacological Properties of Desmopressin -- Pharmacokinetics of Desmopressin -- Fall-Off of Factor VIII Elicited by Desmopressin Administration in Hemophiliacs and von Willebrand’s Disease Patients -- Toxicity of Desmopressin and Related Peptides -- The Hemodynamic and Coagulant Effects of dDAVP are Specific Extrarenal V2-Receptor Responses -- The Vasopressin Antagonist SK&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in vivo -- Non-Responsivess of t-PA, u-PA, and vWF to DDAVP -- III. Desmopressin in Renal Disease -- Control of Bleeding in Uremic Patients -- Hemostatic Effectiveness of Desmopressin in the Bleeding Disorders of Uremia -- Renal Function and Thromboembolism in High Dose Desmopressin Treatment -- IV. Desmopressin and Platelets -- DDAVP Corrects the Platelet Dysfunction Produced by Cardiopulmonary By-Pass, Hemodialysis and Prolonged Storage: Re-Expresion of Glycoprotein Ib on the Platelet Membrane -- Desmopressin in the Treatment of Congenital and Acquired Defects of Platelet Functions -- The Effectiveness of Desmopressin in Patients with Disorders of Primary Haemostasis -- Clinical Efficacy of Desmopressin and Consistency of Responses to Separate Infusion in Patients with Prolonged Bleeding Time Due to Congenital Platelet Defect -- V. Desmopressin and Surgery -- Desmopressin, von Willebrand Factor and Surgery -- Desmopressin in Cardiac Surgery with Extra-Corporeal Circulation -- Desmopressin Corrects the Hemostatic Disorder Induced by Dextran and Regional Anesthesia in Total Hip Replacement -- VI. Desmopressin and Blood Donation -- Effects of Desmopressin on Normal Donors in Plasma Exchange Donations -- The Use of DDAVP in Blood Donors to Increase the Yield of Factor VIII in the Preparation of Factor VIII Concentrates -- VII Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease -- Epidemiology of Mild and Moderate Hemophilia A and von Willebrand’s Disease -- An Overview of Gene Alterations in Mild Hemophilia and von Willebrand Disease -- DDAVP — Clinical Use and Therapeutic Limitations in Patients with Congential Bleeding Disorders: The Auckland Experience -- Multicenter Evaluation of a New Concentrated Desmopressin Preparation (Emosint) Administered Intravenously or Subcutaneously: Analysis of Biological Responses and Side-Effects in 49 Patients with Hemophilia A and von Willebrand’s Disease -- Management of Spontaneous Bleeding and Prevention of Bleeding after Dental Extractions and Other Surgical Procedures in Mild Hemophilia A and von Willebrand’s Disease: Ten Years of Experience at the Vicenza Hemophilia and Thrombosis Center -- Multicenter Italian Study on Subcutaneous Concentrated Desmopressin (Emosint) for the In-Hospital and Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A: Outline of the Project -- Desmopressin: An Overview of Present and Future Indications with a Review of Investigations Performed at the University of Manitoba, 1981–1989 -- VIII. Clinical Applications of Desmopressin in Hemophilia and von Willebrand’s Disease (Second Part) -- Desmopressin in Acquired Hemophilia -- Intravenous and Subcutaneous Desmopressin: Clinical Results -- Intranasal Application of DDAVP: Biological Function, Pharmacokinetics and Reproducibility -- Use of Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders -- Nasal Spray Desmopressin: Laboratory and Clinical Implications -- IX. Side-Effects and Adverse Reactions of Desmopressin -- DDAVP and Tachyphylaxis in Healthy Subjects -- Biological Responses to Repeated Doses of Desmopressin (DDAVP) in Patients with Hemophilia and von Willebrand’s Disease -- Myocardial Infarction and Stroke: Is the Risk Increased by Desmopressin? -- X. Recapitulation -- DDAVP in the Management of Congential and Acquired Bleeding Disorders: Solved and Unsolved Issues. |
|---|